Novocure

Novocure

Herstellung medizinischer Geräte

Root, Switzerland 48.121 Follower:innen

Patient-forward: Aspiring to make a difference in cancer

Info

We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Headquartered in Switzerland, Novocure has U.S. operations in Portsmouth, New Hampshire, Chesterbrook, Pennsylvania and New York City. Additionally, Novocure has offices in Canada, Germany, Jersey, Japan and Israel.

Website
http://www.novocure.com
Branche
Herstellung medizinischer Geräte
Größe
1.001–5.000 Beschäftigte
Hauptsitz
Root, Switzerland
Art
Kapitalgesellschaft (AG, GmbH, UG etc.)
Gegründet
2000
Spezialgebiete
Medical Device, Oncology, Cancer, Glioblastoma und Neuro-Oncology

Orte

Beschäftigte von Novocure

Updates

  • Unternehmensseite von Novocure anzeigen, Grafik

    48.121 Follower:innen

    When you build trust with your colleagues, you can help them innovate. That idea drives Zoey Binder, Manager, North America Compliance and Privacy, as she monitors for compliance risks, reviews policies and agreements, and educates colleagues on how to put policies into practice. A law school internship at Novocure sparked Zoey’s interest in compliance. She saw how she could use her legal and interpersonal skills to help a growing business solve problems in compliant ways. The team was welcoming, introducing her to a variety of legal, regulatory and compliance work. “At Novocure, people really foster a positive environment that encourages you to ask questions and learn,” Zoey said. She interned with us a second time and then joined full-time less than a year post-graduation. Today, Zoey connects with colleagues across North America, and she strives to help all (nearly 700) of them do their jobs better. Before someone pursues an idea, her team can help them understand important parameters to follow. “I love being at a company the size of Novocure because I feel like I can actually impact things,” she said. #WeAreNovocure #patientforward #trust #innovation

    • Kein Alt-Text für dieses Bild vorhanden
  • Unternehmensseite von Novocure anzeigen, Grafik

    48.121 Follower:innen

    Thank you, Hannah Schmidt, for courageously sharing your story! We are proud to be part of Portsmouth Pride. #pride #NewHampshire #WeAreNovocure

    Profil von Hannah Schmidt anzeigen, Grafik

    Care Coordinator II at Novocure

    This weekend I had the privilege of speaking on my experience as a queer employee at Novocure. This year Novocure was the main stage sponsor for Portsmouth Pride. This is the beginning of our collaboration with Seacoast Outright, a non-profit supporting LGBT+ youth and who graciously organized this event. I look forward to more of these opportunities!

  • Unternehmensseite von Novocure anzeigen, Grafik

    48.121 Follower:innen

    “It’s really about the patients,” says Anne Calixte de Lembeye, who leads our growing business in France. How does the team in France live our patient-forward mission? Enable individuals to take responsibilities. Embrace opportunities, and be perseverant. Today, our thriving team lives not only our mission but also our values of drive and trust. “We need to be proactive and trust people we work with,” Anne says. When Anne joined Novocure in 2020, we were just starting our journey to bring our Tumor Treating Fields (TTFields) therapy to patients in France. She was drawn to Novocure because of our innovative therapy and our patient-forward mission. The team in France grew, adding colleagues in market access and medical, then commercial and patient experience, with the objective to continue clinical development in aggressive solid tumors and support the patients with our patient experience team. To view job opportunities in France and around the globe, visit Novocure.com/careers. #patientforward #TTFields #oncology

    • Kein Alt-Text für dieses Bild vorhanden
  • Unternehmensseite von Novocure anzeigen, Grafik

    48.121 Follower:innen

    We are excited to share that in May, we opened our new Global Operations Center (GOC) in Baar, Switzerland. “I would like to congratulate all of our colleagues who carefully planned and diligently executed the physical move of our inventory, the installation of the new warehouse infrastructure and many other tasks related to the move of the GOC,” says Jens Hult, Senior Vice President, Global Supply Chain. The GOC is the constantly beating heart of our Global Operations. Its successful upgrade and relocation required close support from our Quality Control, Regulatory, Facilities and other teams as well as external partners. Our new GOC features almost double the amount of available warehouse space of our previous Operations Center in the Root D4 Business park, around 19km (or 11 miles) away from our new location. With an integrated office space, the new facility allows our warehouse, supply chain, quality assurance and service technician teams to engage and collaborate naturally, to bring our therapy equipment quickly and reliably to our patients. Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer, by developing and commercializing our innovative therapy, Tumor Treating Fields (TTFields). The GOC manages intercompany shipments to our other Operation Centers and warehouses around the world. It is a key part of our evolving global supply chain infrastructure, as we expand into new markets, seek approval in new indications and support ongoing clinical trial activities. The new GOC can service larger inbound and outbound shipments, ultimately enabling us to efficiently serve a growing patient population around the world on TTFields therapy.

    • Kein Alt-Text für dieses Bild vorhanden

Ähnliche Seiten

Aktien

NVCR

NASDAQ

Verzögerung von 20 Minuten

16,04 $

0,04 (0,25 %)

Aktiv
16,01
Niedrig
15,87
Hoch
16,34

Daten von Refinitiv

Mehr Informationen auf Bing

Finanzierung

Novocure Insgesamt 7 Finanzierungsrunden

Letzte Runde

Fremdkapital nach Börsengang

100.000.000,00 $

Investor:innen

Pharmakon Advisors
Weitere Informationen auf Crunchbase